The table below summarizes the significant expense categories regularly provided to the CODM for the six months ended June 30, 2025 and 2024: | | | | | | | | | Six Months Ended June 30, | (in thousands) | | 2025 | | 2024 | Operating expenses: | | | | | | | Research and development: Firmonertinib (excluding personnel-related and other internal costs): | | | | | | | FURTHER | | $ | 5,443 | | $ | 7,334 | FURVENT | | | 19,235 | | | 15,300 | FAVOUR | | | 73 | | | 30 | Other Firmonertinib costs | | | 6,035 | | | 1,569 | Total Firmonertinib | | | 30,786 | | | 24,233 | Research and development: Discovery-stage programs | | | 44,606 | | | 6,614 | Research and development: Personnel-related and other internal costs | | | 13,617 | | | 7,906 | General and administrative: Personnel-related costs | | | 6,792 | | | 4,004 | General and administrative: Other costs | | | 4,594 | | | 3,614 | Other segment items (a) | | | (4,609) | | | (7,080) | Net loss | | $ | (95,786) | | $ | (39,291) |
(a) Other segment items consists of interest and investment income.
|